

Revision date: 20-Feb-2018 Version: 3.2 Page 1 of 7

# 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

**Product Identifier** 

Material Name: Prevnar 13

**Trade Name:** Prevnar 13; PREVENAR; PREVENAR 13 **Synonyms:** Pneumococcal 13-Valent Conjugate Vaccine

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

**Details of the Supplier of the Safety Data Sheet** 

Pfizer Inc Pfizer Ltd
Pfizer Pharmaceuticals Group Ramsgate Road
235 East 42nd Street Sandwich, Kent
New York, New York 10017 CT13 9NJ
1-800-879-3477 United Kingdom

+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300 International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

### 2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

**Label Elements** 

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see

Section 8).

**Note:** This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

Additional Information: Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008. This

substance is not classified as dangerous according to Directive 67/548/EEC.

# 3. COMPOSITION / INFORMATION ON INGREDIENTS

Material Name: Prevnar 13 Page 2 of 7
Revision date: 20-Feb-2018 Version: 3.2

3. COMPOSITION / INFORMATION ON INGREDIENTS				
Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Pneumococcal 13-valent Conjugate	Not Assigned	Not Listed	Not Listed	*
Aluminum phosphate	7784-30-7	232-056-9	Not Listed	*
Polysorbate 80	9005-65-6	Not Listed	Not Listed	*
Saline suspension	MIXTURE	Not Listed	Not Listed	*
Succinate buffer	Not assigned	Not Listed	Not Listed	*

Additional Information: \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has

been withheld as a trade secret.

## 4. FIRST AID MEASURES

**Description of First Aid Measures** 

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

**Exposure:** Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

# 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Formation of toxic gases is possible during heating or fire.

**Products:** 

**Fire / Explosion Hazards:** Fine particles (such as mists) may fuel fires/explosions.

**Advice for Fire-Fighters** 

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

# Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

DZOLIEL

Material Name: Prevnar 13 Page 3 of 7
Revision date: 20-Feb-2018 Version: 3.2

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

## Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

**Collecting:** area thoroughly.

Additional Consideration for Non-essential personnel should be evacuated from affected area. Report emergency

Large Spills: situations immediately. Cleanup operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### **Precautions for Safe Handling**

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:Store in a refrigerator.Storage Temperature:2 - 8 °C (35 to 45°F)

Specific end use(s): Vaccine

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### **Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

### Aluminum phosphate

Russia OEL - TWA 6 mg/m<sup>3</sup>

**Exposure Controls** 

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes.

Personal Protective Refer to applicable national standards and regulations in the selection and use of personal

**Equipment:**protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an

supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and

specific operational processes.

**Hands:** Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.)

**Eyes:** Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations. (Protective clothing must meet the standards in accordance

with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international

equivalent.)

Material Name: Prevnar 13 Page 4 of 7
Revision date: 20-Feb-2018 Version: 3.2

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Homogenous Suspension Color: White

Odor: No data available. Odor Threshold: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

Solvent Solubility:
Water Solubility:
PH:
No data available
No data available
No data available.
No data available.
No data available.
No data available
No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)

Saline suspension No data available

**Pneumococcal 13-valent Conjugate** 

No data available
Aluminum phosphate
No data available
Succinate buffer
No data available
Polysorbate 80
No data available

**Decomposition Temperature (°C):** No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available

Flammablity:

Autoİgnition Temperature (Solid) (°C):

Flammability (Solids):

Flash Point (Liquid) (°C):

Upper Explosive Limits (Liquid) (% by Vol.):

Lower Explosive Limits (Liquid) (% by Vol.):

No data available
No data available

### 10. STABILITY AND REACTIVITY

Reactivity: No data available

**Chemical Stability:** Stable under normal conditions of use.

**Possibility of Hazardous Reactions** 

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep

away from heat sources and electrostatic discharge.

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

**Products:** 

## 11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Material Name: Prevnar 13 Page 5 of 7
Revision date: 20-Feb-2018 Version: 3.2

## 11. TOXICOLOGICAL INFORMATION

Short Term: In the event of accidental injection, an allergic reaction may occur. If an allergic reaction

occurs, the worker should be removed to the nearest emergency room and the appropriate

therapy instituted.

Known Clinical Effects: Based on clinical trials in humans, possible adverse effects following exposure to this

compound may include: swelling, tenderness, .? fever, lack of appetite, irritability, sleepiness (somnolence), sleeplessness, allergic reaction, anaphylactic reactions, headache, nausea,

diarrhea, and vomiting.

# Acute Toxicity: (Species, Route, End Point, Dose)

### Pneumococcal 13-valent Conjugate

Rat Subcutaneous Maximum Non-Lethal Dose .5 mL

Non-human Primate Subcutaneous Maximum Non-Lethal Dose .5mL

### Aluminum phosphate

Mouse Oral LD 50 > 5000 mg/kg Rat Oral LD 50 > 2000mg/kg Rabbit Dermal LD 50 > 4640 mg/kg

### Polysorbate 80

Rat Oral LD50 25 g/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

## Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Pneumococcal 13-valent Conjugate

8 Week(s) Rat Subcutaneous \* 0.5 mL NOAEL None identified \* 0.5 mL 13 Week(s) Rat Subcutaneous NOAEL None identified 13 Week(s) \* 0.5 mL NOAEL None identified Monkey Subcutaneous

Repeated Dose Toxicity Comments: Pneumococcal 13-valent Conjugate: \* Notes: Doses are administrated 1 Dose/2 Weeks.

## Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

## Pneumococcal 13-valent Conjugate

Fertility and Embryonic Development Rabbit Intramuscular 20 times human dose NOAEL No effects at maximum dose,

Not teratogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

## 12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

**Toxicity:** No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

\_\_\_\_\_\_\_\_\_\_\_

Material Name: Prevnar 13 Page 6 of 7
Revision date: 20-Feb-2018 Version: 3.2

Mobility in Soil: No data available

## 13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Additional Information: This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.

# Ingredients:

Pneumococcal 13-valent Conjugate

CERCLA/SARA 313 Emission reporting

California Proposition 65

Not Listed

EU EINECS/ELINCS List

Not Listed

**Aluminum phosphate** 

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Not Eisted

Not

Polysorbate 80

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Not Listed

Not Listed

Present

Present

Material Name: Prevnar 13 Page 7 of 7
Revision date: 20-Feb-2018 Version: 3.2

# 15. REGULATORY INFORMATION

EU EINECS/ELINCS List Not Listed

Saline suspension

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed

Not Listed

Succinate buffer

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed

Not Listed

# 16. OTHER INFORMATION

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal

Protection. Updated Section 11 - Toxicology Information.

Revision date: 20-Feb-2018

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**